Menlo Park, CA
January 6, 2021
Orca Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
MENLO PARK, CA, January 6, 2021 – Orca Bio, a clinical-stage biotechnology company developing high-precision cell therapies for patients with blood diseases, today announced that Ivan Dimov, PhD, Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference. The presentation will be held virtually on Monday, January 11, 2021, at 1:55 PM PT (4:55 PM ET), immediately followed by a Q&A session.
Management will be available for meetings during the week of the conference.
About Orca Bio
Orca Bio is a clinical-stage biotechnology company developing a pipeline of high-precision allogeneic cell therapy therapies with the goal of safely and effectively replacing a patient’s diseased blood and immune system with a healthy one. Orca Bio’s products are biologic cell therapies designed to provide targeted donor cells to patients with the goal of increasing survival rates while decreasing toxicities. The company’s proprietary therapeutic and manufacturing platforms are exclusively licensed from Stanford University. For more information, visit www.orcabio.com. Follow Orca Bio on Twitter: @orcabio.